192 related articles for article (PubMed ID: 29776350)
21. The value of liver function tests in hepatocellular carcinoma.
Lopez JB; Balasegaram M; Thambyrajah V; Timor J
Malays J Pathol; 1996 Dec; 18(2):95-9. PubMed ID: 10879229
[TBL] [Abstract][Full Text] [Related]
22. Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C.
Ezzikouri S; Kimura K; Sunagozaka H; Kaneko S; Inoue K; Nishimura T; Hishima T; Kohara M; Tsukiyama-Kohara K
EBioMedicine; 2015 Jun; 2(6):604-12. PubMed ID: 26288822
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
24. Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study.
Fang AP; Liu ZY; Liao GC; Chen PY; Wang XY; Zhang DM; Luo Y; Long JA; Zhong RH; Zhou ZG; Xu YJ; Xu XJ; Ling WH; Chen MS; Zhang YJ; Zhu HL
Br J Nutr; 2019 Jun; 121(12):1376-1388. PubMed ID: 30935429
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol Restores Neuronal Tight Junction Proteins Through Correction of Ammonia and Inflammation in CCl
Vairappan B; Sundhar M; Srinivas BH
Mol Neurobiol; 2019 Jul; 56(7):4718-4729. PubMed ID: 30377987
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis.
Abdel-Hafiz SM; Hamdy HE; Khorshed FM; Aboushousha TS; Safwat G; Saber MA; Seleem M; Soliman AH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1021-1027. PubMed ID: 29693976
[TBL] [Abstract][Full Text] [Related]
27. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
29. An Easy and Useful Noninvasive Score Based on α-1-acid Glycoprotein and C-Reactive Protein for Diagnosis of Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection.
Omran MM; Emran TM; Farid K; Eltaweel FM; Omar MA; Bazeed FB
J Immunoassay Immunochem; 2016; 37(3):273-88. PubMed ID: 26685049
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients.
Mashaly AH; Anwar R; Ebrahim MA; Eissa LA; El Shishtawy MM
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1503-1508. PubMed ID: 29936723
[TBL] [Abstract][Full Text] [Related]
31. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
32. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.
Wong VW; Yu J; Cheng AS; Wong GL; Chan HY; Chu ES; Ng EK; Chan FK; Sung JJ; Chan HL
Int J Cancer; 2009 Jun; 124(12):2766-70. PubMed ID: 19267406
[TBL] [Abstract][Full Text] [Related]
33. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients.
Carr BI; Guerra V
Int J Biol Markers; 2017 Oct; 32(4):e391-e396. PubMed ID: 28862714
[TBL] [Abstract][Full Text] [Related]
34. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
35. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
[TBL] [Abstract][Full Text] [Related]
36. Rule of changes in serum GGT levels and GGT/ALT and AST/ALT ratios in primary hepatic carcinoma patients with different AFP levels.
Yang JG; He XF; Huang B; Zhang HA; He YK
Cancer Biomark; 2018; 21(4):743-746. PubMed ID: 29286913
[TBL] [Abstract][Full Text] [Related]
37. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
Elemeery MN; Badr AN; Mohamed MA; Ghareeb DA
World J Gastroenterol; 2017 Jun; 23(21):3864-3875. PubMed ID: 28638226
[TBL] [Abstract][Full Text] [Related]
38. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.
Asazawa H; Kamada Y; Takeda Y; Takamatsu S; Shinzaki S; Kim Y; Nezu R; Kuzushita N; Mita E; Kato M; Miyoshi E
Clin Chem Lab Med; 2015 Jan; 53(1):95-102. PubMed ID: 25060348
[TBL] [Abstract][Full Text] [Related]
39. Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.
Jiang L; Li X; Cheng Q; Zhang BH
Tumour Biol; 2015 Sep; 36(9):7167-74. PubMed ID: 25894380
[TBL] [Abstract][Full Text] [Related]
40. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.
Pang Q; Zhang JY; Xu XS; Song SD; Qu K; Chen W; Zhou YY; Miao RC; Liu SS; Dong YF; Liu C
World J Gastroenterol; 2015 May; 21(18):5607-21. PubMed ID: 25987786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
